หน้าแรก
ค้นหา
Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab...
Recorded @ ASCO 2019 Press Briefing, Chicago, June 1, 2019. More info @ http://oncoletter.ch
แสดงข้อมูลเพิ่มเติม 1
Pembrolizumab increases long-term survival in patients with advanced NSCLC
Pembrolizumab Improves 5-Year Survival in Advanced NSCLC in KEYNOTE-001
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC
Long-Term Management on Immunotherapy for Adv. NSCLC: Insights from KEYNOTE-010 (BMIC-066)
Pembrolizumab as Treatment for Oligometastatic NSCLC
The KEYNOTE-024 Precedent for Advanced-NSCLC Treatment
Study finds neoadjuvant nivolumab to show long-term benefit in patients with NSCLC
Nivolumab improves overall survival for advanced kidney cancer
Pembrolizumab new option for firstline treatment of advanced lung cancer with high PDL-1 expression
Dr. Mok Discusses Updated Data With Pembrolizumab in NSCLC
Dr. Garon on the KEYNOTE-001 Study in NSCLC
Dr. Sequist on Pembrolizumab Monotherapy in Nonsquamous NSCLC
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
How pembrolizumab will change the management of advanced lung cancer
KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer
ASCO 2019 Lung Cancer Round Table - New Cancer Research: Long Term Outcomes of Pembrolizumab
Immunotherapy Options for Lung Cancer Variations
KEYNOTE-189: Key Summary of a Practice-Changing Trial in Advanced Non-Squamous NSCLC (BMIC-030)
Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer